Bial Trial Tragedy: No Safety Clue From Similar Products
This article was originally published in Scrip
Executive Summary
Though officially unconfirmed, it is presumed that the fatty acid amide hydrolase inhibitor at the center of the Bial clinical trial disaster is BIA 10-2474, which was in Phase I development for the treatment of "neurological and psychiatric pathologies". But there were few clues to its potential toxicity from previous products with this mechanism of action investigated, and dropped from development.